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In eukaryotic nuclei, genomic DNA is compacted with histone
and nonhistone proteins into a dynamic polymer termed
chromatin. Reorganization of chromatin structure through
histone modifications, the action of chromatin factors, or DNA
methylation, can profoundly change gene expression. These
epigenetic modifications allow heritable and potentially
reversible changes in gene functioning to occur without
altering the DNA sequence, thus extending the information
potential of the genetic code. This review provides an
introduction to epigenetic concepts for renal investigators and
an overview of our work detailing an epigenetic pathway for
aldosterone signaling and the control of epithelial Naþ
channel-a (ENaCa) subunit gene expression in the collecting
duct. This new pathway involves a nuclear repressor complex,
consisting of histone H3 Lys-79 methyltransferase disruptor of
telomeric silencing-1a (Dot1a), ALL1 fused gene from
chromosome 9 (Af9), a sequence-specific DNA-binding protein
that binds the ENaCa promoter, and potentially other nuclear
proteins. This complex regulates targeted histone H3 Lys-79
methylation of chromatin associated with the ENaCa
promoter, thereby suppressing its transcriptional activity.
Aldosterone disrupts the Dot1a–Af9 interaction by serum- and
glucocorticoid-induced kinase-1 phosphorylation of Af9, and
inhibits Dot1a and Af9 expression, resulting in histone H3
Lys-79 hypomethylation at specific subregions, and
derepression of the ENaCa promoter. The Dot1a–Af9 pathway
may also be involved in the control of genes implicated in
renal fibrosis and hypertension.
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For decades, our understanding of gene regulation was based
on the simplistic paradigm that transcription results from
transcription factor binding to a linear DNA sequence,
with subsequent recruitment of the RNA polymerase to the
gene promoter. The idea that all nucleated cells in an
organism contain the same DNA but do not all express the
same genes suggested other mechanisms for gene control.
An explosion of recent work has led to a much more
complex and rapidly evolving model that involves large
multiprotein complexes that serve not only to direct
recruitment of components of the transcription machinery
but also affect chromatin remodeling through histone
modification, DNA methylation, RNA-associated gene
silencing, chromosomal inactivation, and genomic imprint-
ing. As these ‘epigenetic’ controls (so termed because
they change gene activity without altering the DNA sequence
and lead to modifications that can be transmitted to daughter
cells) can vary over time and among cells types, epigenetics
offers potential explanations for how tissue-specific
gene expression is initiated and maintained, and how
environmental influences and aging impact the individual’s
genetic background to produce variations in health
and disease.1 Recent genome-wide studies of epigenetics,
so-called ‘epigenomics,’ using microarray, refinements in
chromatin immunoprecipitation (ChIP), and high through-
put sequencing technologies have enabled analysis of
unique epigenetic signatures and pathways in greater detail,
and have enabled the high-resolution profiling of posttran-
slationally modified histones or histone variants and
transcription factor occupancy sites throughout the genome.
Together with new advances in methods, such as chromatin
conformation capture2 and in vivo chromatin imaging,3 these
studies have broadened our understanding of the long
distance DNA interactions and the structure, organization,
and regulation of chromatin. Epigenomic studies are also
being performed on larger human populations, providing
additional information about phenotypic plasticity in health
and disease, and serving as a rational basis for the design of
new therapeutics.
EPIGENETIC MECHANISMS
Modifications of DNA, microRNAs, and chromatin are major
epigenetic mechanisms controlling gene expression.
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DNA methylation
In vertebrates, DNA methylation involves addition of a
methyl group to the fifth carbon of the cytosine ring
catalyzed by DNA methyltransferases in the context of the
sequence 50-CG-30 (phosphodiester bond between the
cytidine and the guanosine (CpG)). CpG is notably
underrepresented in the human genome, occurring at only
B20% of the expected frequency. However, many regions
(B1 kb long) have a high frequency of CpG, so-called CpG
‘islands.’ Methylation patterns of CpG islands are essential for
gene expression: tissue-specific gene expression is partly
related to different methylation patterns of CpG islands, and
aberrant CpG island methylation patterns are often found in
tumors.4 DNA methylation is typically involved in transcrip-
tional silencing (Figure 1). Promoter methylation may be
dynamic, as it is during development, and sometimes is
targeted specifically to the bodies of active genes. Because
DNA methylation is preserved during DNA replication, it can
be inherited. Although it remains controversial whether
methylation of germline DNA in mammalian genomes is
stably inherited, de novo methylation events are often
observed in a tissue- and disease-specific manner during
somatic cell development and differentiation. For example,
kidney-specific expression of human organic cation trans-
porter 2 is regulated by methylation of the proximal
promoter, interfering with the transactivation by upstream
stimulatory factor 1.5 Tissue-specific expression of the uric
acid transporter 1 gene is coordinated by transcriptional
activation mediated by HNF1a/HNF1b heterodimers and
repression by DNA methylation.6 In contrast, promoter
hypermethylation may silence tumor suppressor genes in
cancers. In renal cell carcinoma, for example, promoter
hypermethylation of several genes has been implicated in
disease pathogenesis.7
MicroRNAs (miRNAs)
MicroRNAs (miRNAs) are a novel and growing class of
endogenous, small, noncoding RNAs that negatively regulate
gene expression involved in cellular proliferation, apoptosis,
differentiation, and other important processes through
degradation or translational inhibition of their target
mRNAs. In the aggregate, miRNAs may directly regulate up
to a third of the genes in the human genome. Nuclear
transcription of miRNA genes leads to generation of double-
stranded RNAs, which are important for generation of the
tightly packed, transcriptionally inactive heterochromatin,
and gene silencing. The RNase III-like enzyme, Dicer, cleaves
these double-stranded RNAs into 21–23 nucleotide small-
interfering RNAs. The small-interfering RNAs unwind and
then incorporate into the RNA-inducing silencing complex,
and the strand complementary to the target mRNA is
incorporated into the RNA-inducing silencing complex.
An endonuclease present within the RNA-inducing silencing
complex either degrades or inhibits translation of
specific mRNA targets, leading to gene silencing (reviewed
in Ref. 8).
miRNAs have diverse temporal and quantitative expres-
sion profiles,9 and are known to reside in operon-like, local
genomic clusters. Differential miRNA expression in renal
cortex and medulla has been reported,10 and miRNAs have
been implicated in renal disease models and acute transplant






















Figure 1 | Epigenetic controls on gene transcription. Transcriptionally silent genes commonly have dense DNA methylation (indicated by
starbursts), a closed chromatin structure, interaction with heterochromatin proteins, and histone modifications such as methylation (Me) or
phosphorylation (P) of histone tails, which are also typically deacetylated. Transcriptionally active genes usually have sparse DNA
methylation, an open chromatin structure, interaction with euchromatin proteins, such as ATP-dependent unwinding enzymes (ATP), and
histone modifications such as acetylation (Ac), that allow access of the DNA to the general transcription factors and various coactivator
proteins.
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downregulates E-box repressors important for TGF-b-
induced Col1a2 expression in diabetic glomerulopathy
models.14 As another example, the transcription factor
E2F3 regulates the Oncomir-1 oncogenic cluster of miRNA
located on chromosome 13. The E2F3–Oncomir-1 axis is
activated in Wilms’ tumor.12 Combined miRNA expression
profiling with gene signature analysis or proteomic techni-
ques has been used to identify miRNA–protein interactions
perturbed in disease states.
Chromatin regulation and Dot1a
DNA strands wrap around histone octamers, forming
nucleosomes that are organized into chromatin, the building
blocks of chromosomes. The nucleosome is the basic
repeating unit of chromatin and includes two copies of each
of the four core histones H2A, H2B, H3, and H4 wrapped by
146 bp of DNA (Figure 2). Each core histone is composed of
a structured domain, the histone fold, and two tails. Histone
tails are necessary for establishing transcriptionally repressive
chromatin and for interactions between nucleosomes (re-
viewed in Ref. 15). DNA packaging into chromatin compacts
the DNA into the nucleus, but also presents a barrier for
regulatory factors to interact with the DNA. Reversible
changes in chromatin organization influence gene expression:
genes are actively transcribed when the chromatin is open,
but silent when the chromatin is condensed. The net effects
of nucleosome assembly, stability, mobilization, and disas-
sembly influence gene transcription. Replication-coupled
nucleosome assembly, which places dimeric subunits behind
the replication fork or at sites of active processes that
mobilize preexisting nucleosomes, maintains transcription-
ally silent chromatin. Nucleosome-positioning sequences,
adenosine triphosphate-dependent nucleosome remodelers,
histone chaperones, posttranslational modifications and
histone variants regulate nucleosomal stability.16
Reversible and site-specific histone modifications can
occur at multiple sites through acetylation, methylation,
phosphorylation, ubiquitylation, sumoylation, adenosine
diphosphate (ADP) ribosylation, deimination, and proline
isomerization (Figure 1). Dynamic regulation of these
modifications, position- and modification-specific protein
interactions, and biochemical crosstalk between modifica-
tions leads to further complexity in choreographing tran-
scription.17 In addition to the histone-marking (also known
as the ‘histone code’18) model of epigenetic inheritance,
dynamic histone turnover facilitates continuous access to
DNA-binding proteins that may also propagate active
chromatin. How chromatin-modifying enzymes engage their
nucleosomal substrates in vivo remains an important
question. Protein ‘code readers’ bind to specific sets of
histone modifications leading to downstream effects, such as
gene transcription, DNA synthesis and repair. Certain protein
domains bind modified histones.19 For example, the
bromodomain binds acetyl-lysine, and the chromodomain
binds methyl-lysine.
Histone acetyltransferases catalyze addition of acetyl
groups to the N-terminal tail of a histone octamer. This
modification reduces the affinity of histones for DNA and
allows RNA polymerase and transcription factors to access
the promoter (Figure 1). In contrast, histone deacetylases
remove acetyl groups and generally allow transcriptional
repression. There is often an interplay between DNA
methylation and histone acetylation/methylation. Transcrip-
tionally active regions are typically unmethylated DNA with
acetylated histones, whereas repressed regions typically
include methylated DNA with deacetylated histones (Fig-
ure 1). Histone methylation occurs on arginine and lysine
residues. Histone arginine methylation is typically involved in
activation of genes in which methylases are recruited as
coactivators. The coactivator-associated arginine methyl-
transferase 1/protein arginine methyltransferase 1 family of
histone methyltransferases (HMTs) functions in this manner
and targets histones H3 or H4.20 In contrast, the suppressor
of variegation, enhancer of zeste, and trithorax domain
family of lysine HMTs silences genes. The Suvar39 enzyme
was the first such enzyme described; it was found to
methylate histone H3 Lys-9 and to be recruited by
corepressors.21 More recently, a third class of HMTs
represented by yeast disruptor of telomeric silencing-1
(Dot1) and its human homologue, DOT1L, were de-
scribed.22,23 These HMTs lack a suppressor of variegation,
enhancer of zeste, and trithorax domain and affect gene
silencing by methylation of Lys-79 in the histone H3 globular





















Figure 2 | Schematic model of a nucleosome and histone H3.
Nuclear DNA is compacted and condensed in chromatin. The
basic building block of chromatin is the nucleosome, which
contains histone octamers. The histone tails are subject to a
variety of posttranslational modifications, including methylation
by methyltransferases such as protein arginine methyltransferase
6 (PRMT6), acetylation by acetyltransferases such as histone
acetyltransferase (HAT) or Sirt1, and phosphorylation by kinases
such as protein kinase C-related kinase 1 (PRK1). Dot1a specifically
methylates Lys79 in the globular domain of histone H3. These
histone modifications often exert epigenetic control of target
gene transcription. For the purpose of illustration, the positions of
the modified amino acids are not drawn to scale.
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mediator of telomeric silencing in yeast and is highly
conserved from yeast to humans.24 It has also been shown
to be important for meiotic checkpoint control during the
cell cycle25 and for localization and association of Sir
silencing proteins in yeast.26
Mono-, di- and trimethylation states of lysines on histones
often lead to different functions. Histone H2B monoubiqui-
tination by Rad6/Bre1 affects H3 Lys-79 trimethylation by
enhancing synthesis of all H3 Lys-79 methylation states.27
Moreover, charge-based interactions of basic patch residues
of the histone H4 N terminus and an acidic patch at the Dot1
C terminus are important for histone H3 Lys-79 methylation
in a trans-histone regulatory pathway.28 Recruitment of Dot1
or DOT1L to methylate histone H3 Lys-79 has been
associated with both gene activation and repression. Similar
bimodal effects on transcription have been attributed to
histone H3 serine-10 phosphorylation.29 Using direct
sequencing of ChIP DNA to map human genome-wide
distributions of histone modifications and chromatin protein
target sites, Barski et al.30 reported that monomethylations of
H3 Lys-27, H3 Lys-9, H4 Lys-20, and H3 Lys-79 correlate
with gene activation, whereas trimethylations of H3 Lys-27,
H3 Lys-9, and H3 Lys-79 are linked to repression. Indeed, we
found that overexpression of Dot1a-enhanced green fluor-
escent protein constructs in mIMCD3 cells increased
methylation of histone H3 Lys-79 but not H3 Lys-431 and
basally repressed epithelial Naþ channel-a (EnaCa) tran-
scription.32 In contrast, another group found that DOT1L
and MLL, an H3 Lys-4 methyltransferase, preferentially
cooccupy the proximal transcribed region of active genes,
correlating with enrichment of di- and trimethylated H3 Lys-
79 and trimethylated H3 Lys-4. Thus, coordinate recruitment
of these two methyltransferases might demarcate enhancer
regions.33 Interestingly, the MLL1 gene can undergo trans-
locations with partner genes, including ALL1 fused gene from
chromosome 9 (Af9), that encode proteins that bind to
DOT1L and Dot1a, but lack the native H3 Lys-4 methyl-
transferase domain. Thus the Dot1a–Af9 complex we describe
for the control of ENaCa transcription favors H3 Lys-79
methylation at the expense of H3 Lys-4 methylation, and thus
represses ENaCa transcription. Combinatorial interactions of
various HMTs and demethylases likely dictate the ‘ON’ or
‘OFF’ mode of transcription for specific genes.
In early work, our laboratory cloned the mouse Dot1 gene,
characterized its genomic organization, and in vivo expres-
sion.31 The gene contains 28 exons on chromosome 10qC1,
with exons 24 and 28 further divided into two and four
sections, respectively. Alternative splicing in exons 3, 4, 12,
24, 27, and 28 gives rise to five Dot1 mRNAs (Dot1a–Dot1e).
Dot1a is closest to its human counterpart DOT1L, sharing
84% amino-acid identity across its 1,540 amino acids. The
1,114 amino-acid protein mDot1b is truncated at its N- and
C-termini and contains an internal deletion. Dot1c–Dot1e are
incomplete at the 50-end. The functional importance of
Dot1b–e is unknown. Northern analysis with probes
corresponding to the methyltransferase domain or the
Dot1a-coding region detected 7.6 and 9.5 kb transcripts in
multiple mouse tissues, but only the 7.6 kb transcript was
evident in mIMCD3-collecting duct cells.
Dot1a AND THE EPIGENETIC CONTROL OF ENaCa GENE
EXPRESSION
ENaC is involved in Naþ reabsorption in the distal tubule,
and hence the regulation of Naþ balance, extracellular fluid
volume, and blood pressure,34 as evidenced by the findings of
ENaC mutations associated with the genetic hypertensive and
hypotensive diseases, Liddle’s syndrome35 and pseudohypoal-
dosteronism type 1.36 ENaC is expressed in the apical
membrane of salt-absorbing epithelia of kidney, distal colon,
and lung airways, where it constitutes the rate-limiting step
in active Naþ and fluid absorption. ENaC consists of three
homologous subunits—a, b, and g—encoded by the Scnn1a,
Scnn1b, and Scnn1c genes.
ENaC is an important molecular target of aldosterone.
Increased circulating mineralocorticoids increase extracellu-
lar fluid volume and blood pressure, in large part by
activation of ENaCs.37 Aldosterone has complex, and
temporally distinct actions on ENaC expression, with both
immediate (o3 h) effects, attributed to increased trafficking
or activity of ENaC in the apical membrane, and delayed
actions (43 h) that involve the synthesis of new ENaC
subunits.38–40 In the cortical collecting duct, aldosterone
administration or hyperaldosteronism induced by a low-Naþ
diet increases ENaCa gene transcription, without increasing
b- or g-subunit expression,41 and this response appears to be
rate limiting for ENaC activity in this segment. Moreover,
aldosterone does not alter ENaCa mRNA turnover.37 Hence,
the focus of our work has been the control of ENaCa
transcription.
Under basal conditions, ENaCa gene transcription is
constrained, but it can be induced not only by aldosterone,
but also other stimuli, including the immediate early gene
serum- and glucocorticoid-induced kinase-1 (Sgk1) even in
the absence of steroids.42 Sgk1 responds quickly to changes in
serum aldosterone levels, which can rapidly change over a
narrow range in response to minor, reciprocal changes in
dietary salt intake. Sgk1 can rapidly promote increased apical
density of ENaC channels by disinhibiting Nedd4-2-triggered
internalization and degradation of ENaCa subunits.
The biological actions of aldosterone on target gene
transcription have generally been attributed to aldosterone’s
interaction with the mineralocorticoid receptor and the
liganded receptor’s binding to hormone response elements in
the ENaCa promoter. However, the available data suggest
that both hormone response element-dependent and -
independent mechanisms control ENaCa transcription, and
tissue-specific transcriptional controls on the gene are
operative.43 Aldosterone also induces Sgk1 transcription
through mineralocorticoid receptor-/hormone response ele-
ment-dependent mechanisms.44
The mechanisms underlying this basal repression and its
release during gene induction have not been established. We
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hypothesized that chromatin-based transcriptional repression
and derepression mechanisms might operate coordinately
with the classical pathway of aldosterone-mediated transacti-
vation of the ENaCa gene by liganded nuclear hormone
receptors. We discovered such an epigenetic pathway that
involves combinatorial interactions of Dot1a, the DNA-
binding protein Af9,45 and Sgk1. Because mIMCD3 cells
retain phenotypic properties of the inner medullary collect-
ing duct in vivo, respond to aldosterone, and express the
components involved in the novel aldosterone signaling
network reviewed here, we have used mIMCD3 cells as our
model. We manipulated Dot1a expression by overexpression
or by RNA interference to analyze signaling events involved
in basal and aldosterone-stimulated ENaCa transcription. We
hypothesized that Dot1a-mediated histone methylation at the
ENaCa promoter alters local chromatin structure so as to
suppress ENaCa transcription, and that suppression of Dot1a
activity allows ENaCa transcription to proceed (Figure 3).
Consistent with our hypothesis, overexpression of enhanced
green fluorescent protein-tagged Dot1a resulted in hyper-
methylation of histone H3 Lys-79 at the endogenous ENaCa
promoter, repression of endogenous ENaCa mRNA expres-
sion, and decreased activity of a stably integrated ENaCa
promoter-luciferase construct. The histone H3 Lys-79
hypermethylation and repression of ENaCa promoter activity
required Dot1a’s methyltransferase activity, because methyl-
transferase-dead mutants did not cause these effects.46 The
Dot1a effect was substantial, because knockdown of Dot1a
resulted in at least a tripling of endogenous ENaCa mRNA
expression and of the activity of a stably integrated ENaCa
promoter–reporter gene.46 We next postulated that one
action of aldosterone to enhance ENaCa transcription is to
relieve the Dot1-mediated basal repression. Indeed, aldoster-
one treatment resulted in downregulation of mDot1a mRNA
levels in mIMCD3 cells, histone H3 Lys-79 hypomethylation
in bulk histones and at specific sites in the ENaCa 50-flanking
region, transactivation of the stably integrated ENaCa
promoter-luciferase construct, and increased expression of
endogenous ENaCa mRNA.46
Although Dot1a has been shown to have non-sequence-
specific DNA-binding activity, it had not been reported to
have sequence-specific DNA-binding activity that would
allow it to interact with the ENaCa promoter. Accordingly,
we sought to identify Dot1a protein-binding partners that
would confer sequence-specific DNA-binding activity for the
complex. Using the yeast two-hybrid assay with Dot1a as bait
to screen a mouse kidney cDNA library ligated to the GAL4
activation domain, we identified a specific interaction
between Dot1a and the protein encoded by Af9, a putative
DNA-binding protein.32 This interaction was confirmed by
multiple in vitro and in vivo methods, including coimmu-
noprecipitation assays, mammalian two-hybrid assays, and
glutathione S-transferase pull-down assays. The two proteins
colocalized in the nucleus of mIMCD3 cells. ChIP assays
confirmed that Af9 and Dot1a coassociate with chromatin at
specific regions of the ENaCa promoter.32 In preliminary
reports, we have identified three partially conserved Af9-
binding sites in the ENaCa 50-flanking region by DNase I
footprinting (Zhang W., Xia X., Reisenauer M., et al.,
Abstract). Domain mapping of Dot1a and Af9 revealed that
Dot1a aa 479–659 and 829–972 are capable, but less than the
full length of Dot1a, to mediate the interaction with Af9.32
The Dot1a methyltransferase domain (aa 1–416), the putative





















Figure 3 | Model of Dot1a–Af9-mediated transcriptional repression and aldosterone- and Sgk1-induced derepression of the ENaCa
gene. Under basal conditions, the histone H3 methyltransferase Dot1a and the DNA-binding protein Af9 are complexed with chromatin
associated with specific regions of the ENaCa 50-flanking region. This presumably facilitates the ability of Dot1a to hypermethylate Lys79 of
histone H3, leading to a chromatin configuration that suppresses ENaCa transcription. Aldosterone downregulates the expression of both
Dot1a and Af9, leading to decreased abundance of the repressor complex. Aldosterone also induces Sgk1, which phosphorylates Ser435 of
Af9, causing disruption of the protein–protein interactions of Dot1a and Af9. This results in hypomethylation of histone H3 Lys79 and
release of transcriptional repression of the ENaCa gene, contributing in large measure to the effects of aldosterone to increase ENaCa gene
transcription. The contributions of the liganded mineralocorticoid receptor and the putative histone H3 Lys79 demethylase (designated by
‘DM?’ and the dashed arrow) to this dynamic process remain under investigation.
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part (aa 1,112–1,540) apparently are not necessary for the
interaction.
We next tested the functional consequences of the
Dot1a–Af9 interaction on basal ENaCa transcription. Our
hypothesis that Af9 binds to the ENaCa promoter, and
through its interaction with Dot1a, represses ENaCa
transcription by increasing the local level of chromatin-
associated histone H3 Lys-79 methylation at the ENaCa
promoter was confirmed through multiple complementary
methods (Figure 3). Overexpression of Af9 resulted in
hypermethylation of H3 Lys-79 at specific subregions of the
endogenous ENaCa promoter, and repression of endogenous
ENaCa mRNA expression and ENaCa promoter-luciferase
constructs. Importantly, overexpression of Af9 together with
Dot1a synergistically inhibited expression of endogenous
ENaCa in mIMCD3 cells. Conversely RNA interference-
mediated knockdown of Af9 caused the opposite effects.32
ChIP assays revealed that overexpressed FLAG-Af9, endo-
genous Af9, and Dot1a are each associated with the ENaCa
promoter. Aldosterone inhibited Af9 expression at both
mRNA and protein levels in a coordinate manner with
Dot1a. Collectively, these data indicated that Dot1a and Af9
form a nuclear complex that, under physiological conditions,
associates with specific sites of the ENaCa promoter, leading
to targeted hypermethylation of histone H3 Lys-79 and
repression of ENaCa transcription (Figure 3). This mechan-
ism appears to be more broadly applicable to other
aldosterone-inducible genes, because Af9 overexpression
alone or in combination with Dot1a inhibited mRNA levels
of three other aldosterone-inducible genes—connecting
tissue growth factor, preproendothelin, and period homo-
log—in mIMCD3 cells.32
We then demonstrated that both Sgk1 and Af9 associate
with the ENaCa promoter and that Sgk1-dependent
phosphorylation of Ser435 within Af9 reduces the Dot1a–Af9
interaction, inhibiting Dot1a association with the ENaCa
promoter, and leading to targeted histone H3 Lys79
hypomethylation at the ENaCa promoter and derepression
of ENaCa transcription47 (Figure 3). The in vivo correlate of
these observations was demonstrated in wild type and Sgk1
null mice subjected to manipulation of dietary salt intake. As
expected, wild-type mice maintained on a low-salt diet
exhibited coordinately enhanced levels of renal ENaCa
protein expression and Af9 phosphorylation. Conversely,
Sgk1 null mice exhibited reduced levels of Af9 phosphoryla-
tion and ENaCa mRNA levels when placed on a low-salt diet
compared with wild-type mice fed the same diet.47
Definition of the full complement of proteins and their
interaction in the Dot1a–Af9 nuclear complex will be critical
to understanding the function and regulation of its activity
and of ENaCa transcription. Our most recent work has
provided preliminary evidence for functional and physical
interaction of the NADþ -dependent deacetylase Sirt1, a
homologue of yeast Sir2, with Dot1a in regulating ENaCa
gene expression (Zhang W., Xia X., Reisenauer M., et al.,
Abstract). Sirt1 targets histone and select nonhistone
proteins, and is involved in gene silencing, aging, and
oxidative stress responses.48–50 In mice, we found that Sirt1 is
highly expressed along the collecting duct, and that chronic
aldosterone treatment inhibits its expression. In mIMCD3
cells, Sirt1 overexpression or treatment with the Sirt1
activator resveratrol dramatically inhibited basal and aldos-
terone-induced ENaCa promoter activity. Conversely, Sirt1
knockdown or inhibition of its activity with nicotinamide
significantly enhanced ENaCa promoter activity. Coexpres-
sion of Sirt1 and Dot1a synergistically inhibited ENaCa
promoter activity. Overexpression of Sirt1 inhibited endo-
genous ENaCa mRNA levels, whereas small-interfering RNAs
knockdown of Sirt1 increased them. In ChIP assays,
endogenous Sirt1 associated with four regions of the ENaCa
promoter known to associate with Dot1a. Aldosterone
inhibited Sirt1 association at two of these regions. Sirt1 and
Dot1a coimmunoprecipitated from mIMCD3 cells, and when
coexpressed in human embryonic kidney 293-T cells,
colocalized in the nucleus. Thus, Sirt1 appears to be a
component of the Dot1a repressor complex. Confirmation of
these findings and determining whether Sirt1 acts through
changes in acetylation or adenosine diphosphate ribosylation
of histone and/or nonhistone targets are currently being
pursued.
Finally, although a demethylase specific for histone H3
Lys-79 has not yet been identified, we speculate that the effect
of aldosterone to derepress ENaCa transcription may involve
not only relief of the basal inhibitory effects of Dot1a on the
gene, but also recruitment and action, perhaps involving the
liganded mineralocorticoid receptor, of a corresponding
histone H3 Lys-79 demethylase (Figure 3). It has been
proposed that distinct combinations of HMTs and histone
demethylases write a histone code for promoter-specific,
signal-dependent transcription. In this paradigm, HMTs may
impose gene-specific, inhibitory ‘gatekeeper’ functions to
prevent unliganded nuclear receptors, such as the estrogen
receptor-a, and other classes of regulated transcription
factors, from constitutively binding to and activating their
target gene promoters when activating signals are absent.
This ‘gatekeeper’ function is overcome on binding of
liganded receptors and recruitment of specific histone
demethylases that permit ligand- and signal-dependent gene
activation.51
POTENTIAL RELEVANCE TO HEALTH AND DISEASE
The relevance of this novel pathway in health and disease is
presently open to conjecture, but we agree with Pearce and
Kleyman52 that the Dot1a–Af9 complex as a transcriptional
effector mechanism of Sgk1 signaling offers significant
efficiency, agility, and capacity in meeting the demands on
renal salt excretion in response to acute and chronic changes
in dietary salt intake. We also speculate that dysregulation of
the Dot1a–Af9 complex may lead to disorders of renal Naþ
excretion, and, thus, potentially abnormal blood pressure
phenotypes in humans, much the same as activating or
inactivating mutations in ENaC lead to monogenic forms of
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Naþ retention and hypertension (Liddle’s syndrome) or
renal Naþ wasting and hypotension (pseudohypoaldoster-
onism type 1).34 Moreover, aldosterone has clinical effects
beyond its regulation of Naþ balance, in particular, the
promotion of cardiac and renal fibrosis.53,54 As one of the
genes we found to be regulated by the Dot1a–Af9 complex,
connective tissue growth factor, promotes cardiac and renal
fibrosis in experimental models, we speculate that distur-
bances that inactivate the Dot1a–Af9 pathway and conse-
quently derepress connecting tissue growth factor
transcription could accelerate heart and kidney pathology.
Given the growing interest in epigenomics and the increased
technological sophistication, it is likely that epigenetic
pathways will be discovered that govern the regulation of a
large array of genes of relevance to renal physiology and
disease.
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